Johns Hopkins University NCTN Lead Academic Site Program

约翰·霍普金斯大学 NCTN 牵头学术网站项目

• 批准号: 8605317
• 负责人: DEBORAH K ARMSTRONG
• 金额: $ 63.96万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-04-15 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8605317
• 关键词: American College of Radiology Imaging Network; Award; Biological Markers; Breast; Cancer Center; Cellular biology; Cervix Uteri; Clinical; Clinical Protocols; Clinical Trials; Clinical Trials Network; Collaborations; Comprehensive Cancer Center; Contracts; Correlative Study; Data Quality; Development; Disease; Early Diagnosis; Eastern Cooperative Oncology Group; Faculty; Fostering; Goals; Grant; Gynecologic Oncology Group; Head and neck structure; Image; Institution; Laboratories; Lead; Leadership; Lung; Malignant Neoplasms; Malignant neoplasm of prostate; Mission; Modality; Molecular Biology; Patients; Performance; Pharmaceutical Preparations; Phase; Principal Investigator; Process; Public Health; Public Health Schools; Quality of life; Radiation; Radiosurgery; Research; Role; Science; Site; Staging; Techniques; Therapeutic; Translational Research; Universities; cancer prevention; cancer therapy; innovation; member; novel; oncology; pre-clinical; programs; public health relevance; screening; therapeutic development

DESCRIPTION (provided by applicant): Johns Hopkins has been an academic member institution of cooperative groups since the founding of this national oncology research in 1955. Over the decades, our faculties have provided strong clinical and laboratory scientific leadership and administrative leadership to the cooperative groups. Our primary goal is to bring innovative translational science developed in pre-clinical and early phase trials at Johns Hopkins to the National Clinical Trials Network for further development. In conjunction with this, our faculties serve in leadership roles as study chairs and laboratory co-chairs, disease and modality-oriented committee chairs. The majority of our contributions and our longest association has been with ECOG (now ECOG-ACRIN) and secondly, with GOG (now NRG).The specific aims are: 1) To integrate all of the cooperative group activities within one administrative program at Johns Hopkins to foster a coordinated, collaborative and inclusive process of prioritization of trials and the facilitation of trial activation and accrual. 2) To promote participation in innovatve, multi-modality treatments in cancer with a focus on imaging, radiation, surgery, novel systemic therapeutics and biomarkers. 3) To continue to provide scientific leadership in the NCTN groups and there, disease-oriented committees and promote the involvement of junior faculty. 4) To continue to bring correlative translational research, novel imaging and radiation techniques, cell biology and molecular biology into clinical protocols for all stages of disease. 5) To continue to expand accrual, provide efficient and timely trial activation, and to maintain excellent performance in data quality. These goals will be accomplished through the mission of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The Center has achieved excellence in translational research with the awarding of six SPORE grants (cervix, Gl-cancer, prostate, breast, lung, head and neck). In addition, early clinical trials of new drugs are conducted under the NCI phase 1 contract (since 1982). The Early Therapeutics Development with Phase II Emphasis grants allows the development of laboratory science and imaging correlative studies. The recent expansion of Center facilities enhances clinical trial accrual.

描述（申请人提供）：约翰霍普金斯大学自1955年成立国家肿瘤学研究以来，一直是合作团体的学术成员机构。几十年来，我们的院系提供了强有力的临床和实验室的科学领导和行政领导的合作团体。我们的主要目标是将约翰霍普金斯在临床前和早期试验中开发的创新转化科学引入国家临床试验网络，以进一步发展。与此同时，我们的教师担任研究主席和实验室联合主席，疾病和模式为导向的委员会主席的领导角色。我们的大部分贡献和最长的合作关系是与ECOG（现在的ECOG-ACRIN）合作，其次是与GOG（现在的NRG）合作。具体目标是：1）将所有合作小组活动整合到约翰霍普金斯的一个管理计划中，以促进协调、协作和包容的试验优先级排序过程，并促进试验激活和累积。2)促进参与癌症的创新，多模式治疗，重点是成像，放射，手术，新型全身治疗和生物标志物。3)继续在NCTN团体和疾病导向委员会中提供科学领导，并促进初级教师的参与。4)继续将相关的转化研究、新型成像和放射技术、细胞生物学和分子生物学纳入疾病各个阶段的临床方案。5)继续扩大权责发生制，提供高效及时的试验激活，并保持数据质量方面的优异表现。这些目标将通过约翰霍普金斯的西德尼·金梅尔综合癌症中心的使命来实现。该中心在转化研究方面取得了卓越成就，获得了六项SPORE赠款（宫颈癌，GI癌，前列腺癌，乳腺癌，肺癌，头颈部）。此外，新药的早期临床试验是根据NCI第一阶段合同进行的（自1982年以来）。早期治疗发展与第二阶段重点赠款允许实验室科学和成像相关研究的发展。最近中心设施的扩建提高了临床试验的收益。